LIG1 and frontotemporal dementia: Although more studies are needed to validate its therapeutic potential, the targeted delivery of Lig1 to mitochondria represents a significant step towards addressing the unmet medical need not only in FUS-associated ALS/FTD, but also in other disorders associated with mitochondrial dysfunction.